University of Toronto, 5 Fairview Mall Drive, Suite 170, Toronto, ON, Canada.
Expert Rev Vaccines. 2014 Aug;13(8):943-68. doi: 10.1586/14760584.2014.933674. Epub 2014 Jul 2.
Safe and effective combination pediatric vaccines are necessary to simplify complex immunization schedules and to improve coverage and protection for children worldwide. We provide an overview of the 18 years of clinical and worldwide experience with DTaP-IPV-Hib (Pediacel(®)), a unique fully liquid pentavalent vaccine (diphtheria [D], tetanus [T], acellular pertussis, inactivated poliovirus [IPV], Haemophilus influenzae type b [Hib]). Pediacel has demonstrated good and lasting immunogenicity in many populations, with differing primary series and booster schedules, and with a variety of coadministered vaccines. The acellular pertussis antigens have proven efficacy and real-world effectiveness. Clinical and post-marketing studies confirm the safety of Pediacel. Pediacel can be used for primary series and toddler booster doses, as well as in mixed pediatric vaccine schedules.
安全有效的联合儿科疫苗对于简化复杂的免疫计划以及提高全球儿童的覆盖率和保护率是必要的。我们提供了 DTaP-IPV-Hib(Pediacel(®))18 年的临床和全球经验概述,这是一种独特的全液体五价疫苗(白喉[D]、破伤风[T]、无细胞百日咳、灭活脊髓灰质炎病毒[IPV]、流感嗜血杆菌 b 型[Hib])。Pediacel 在许多人群中表现出良好且持久的免疫原性,具有不同的基础系列和加强剂方案,并与各种联合疫苗一起使用。无细胞百日咳抗原已被证明具有疗效和实际效果。临床和上市后研究证实了 Pediacel 的安全性。Pediacel 可用于基础系列和幼儿加强剂量,也可用于混合儿科疫苗方案。